April 2023 marks five years since Medicines Discovery Catapult (MDC), an independent, not-for-profit national innovation centre for drug discovery, actively began reshaping drug discovery for patient benefit.
To mark this milestone, MDC has launched an impact showcase site, offering an immersive insight into a selection of MDC's work through the lens of its collaborations and initiatives.
In a move that will build on its leading position in the market and bring together experts across the business, Partners& has launched a national science and technology practice.
In line with the UK government’s commitment to focusing on the growth and development of this important part of our economy, Partners& is positioning itself to deliver a unique proposition to this complex, fast moving and innovative sector.
Check out your monthly round up of employee engagement opportunities in this month's People Pathways newsletter!
Arecor Therapeutics plc
(“Arecor” or the “Group”)
US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES
- Endorses potential of proprietary Arestat™ platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market
- Further strengthens Group’s extensive patent portfolio
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women’s health, has announced a collaborative services agreement between Physiomics PLC and ValiRx subsidiary company, Inaphaea BioLabs Ltd.
Based in Oxford, Physiomics is a leading oncology consultancy that uses mathematical models to support the development of cancer treatment regimens and personalised medicine solutions.
In this episode senior associate and patent attorney Paul Roscoe, and partner, solicitor and trade mark attorney Chris Hoole, are joined by 3D printing specialist and CEO/co-founder of Promake, Professor Jason Laing.
This episode will help manufacturers to understand the IP risks associated with 3D printing, how smart materials could provide anti-counterfeiting measures, and the direction of innovation in this technology area.
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
Stevenage, UK, 26 April 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as independent Non-Executive Chair.
Jonathan’s appointment reflects the maturation of the company, having closed its series A financing of £16m in late 2022.
• Agreement grants access to patient genotypes and clinical data curated by Professor Ammar Al-Chalabi’s Group based at King’s College London
• Motor Neurone Disease (MND) Association supports new analysis of patient data to bring cutting edge analysis tools to improve understanding of disease
• Enables PrecisionLife to establish precision neuroscience R&D partnerships to advance new patient stratification biomarkers, diagnostics and treatment approaches
Cambridge and Saffron Walden, UK, 21st April 2023 / Sciad Newswire / Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period.